Seely Lynn sold $7K of LYEL
Seely Lynn (President and CEO) sold 388 shares of Lyell Immunopharma, Inc. (LYEL) at $18.91 on 2026-05-11.
How this was made
The 30-second read
Why it matters
This provides a new, timestamped data point on CEO share disposition but does not include any operational, clinical, or financial update.
Market read
Traders may note the CEO’s selling as a minor sentiment input, but there is no fundamental catalyst in the text.
What to watch
Insider sales should be interpreted alongside prior Form 4 activity, total insider ownership changes, and any concurrent corporate/clinical catalysts not mentioned here.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Lyell Immunopharma, Inc.
Ticker impact
Lyell Immunopharma CEO Seely Lynn filed an open-market sale of 388 shares at $18.91 on 2026-05-11 via SEC Form 4.
Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and short-lived.
The filing is a small, open-market sale with no 10b5-1 plan stated; however, Form 4 insider sales are common and this transaction size is modest versus company scale.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
The sale may be for diversification, taxes, or pre-planned liquidity needs; without a stated 10b5-1 plan, it still doesn’t imply negative fundamentals.
Key entities
- issuerLyell Immunopharma, Inc.
Subject of the Form 4 insider transaction disclosure (LYEL).
- insiderSeely Lynn
President and CEO who sold 388 shares in an open-market transaction.